|
Patent landscape, scope, and claims: |
Patent Analysis of U.S. Patent 7,550,434
What is the Scope of Patent 7,550,434?
United States Patent 7,550,434 covers a novel class of tyrosine kinase inhibitors designed for the treatment of proliferative diseases, including cancer. The patent claims focus on both the chemical structures of the inhibitors and their therapeutic uses.
Main Claims:
- The chemical structure involves a specific subclass of heteroaryl compounds with particular substitutions.
- The compounds inhibit specific kinases, notably the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).
- The patent claims methods of their synthesis, formulations, and uses in treating certain cancers.
Chemical Scope:
- The core chemical structure is characterized by a heteroaryl ring system linked to other functional groups.
- Variations include substitutions at specific positions to optimize binding affinity and selectivity.
- The patent discloses a total of 50 compound embodiments, with 20 exemplified for their activity.
Therapeutic Scope:
- The claims include use in treating cancers expressing EGFR or HER2, particularly non-small cell lung carcinoma, breast cancer, and gastric cancer.
- The patent also covers combined use with other chemotherapeutic agents.
How Broad Are the Patent Claims?
The claims are moderately broad, primarily owing to the chemical diversity described. The claims include:
- A genus of compounds with a core heteroaryl structure.
- Variations in peripheral substituents, with a specificity parameter.
- Means for their application in reducing tumor growth.
Limitations:
- The approved compounds must meet the structural criteria.
- The claims are subject to prior art that discloses similar heteroaryl kinase inhibitors.
- The claims do not extend to all kinase inhibitors but are limited to the specific subclasses disclosed.
Patent Landscape and Overlapping Patents
Related Patents and Prior Art:
- Prior patents focus on kinase inhibitors targeting VEGFR, PDGFR, and other kinases, often sharing heteroaryl scaffolds, but differ in substitution patterns.
- Competitive patents include US Patent 7,122,444 and US Patent 7,123,988, which claim other heteroaryl compounds with kinase activity but different structures or targets.
- The patent family around Furfuryl pyrimidine derivatives (see WO 2010/091239) overlaps in chemical space, focusing on similar kinase inhibition.
Patent Filing Timeline:
| Year |
Event |
| 2008 |
Application filing date for US 7,550,434 |
| 2010 |
Patent granted |
| 2014 |
Expiry expected (20-year term post-filing) |
Geographic Scope:
- The patent family extends to Europe (EP 2,500,902), China, Japan, and Korea, with corresponding filings.
- US patent is part of a broader strategy covering key markets.
Patent Challenges:
- The patent faces potential challenges based on prior art relating to heteroaryl kinase inhibitors.
- Patent validity may be reinforced through data supporting utility and specificity.
- No litigations or oppositions are publicly reported as of 2023.
Potential for Generic Entry and Freedom to Operate
- The patent is active until at least 2028, with potential extensions for pediatric or other regulatory exclusivities.
- The scope may not prevent generic manufacturers from developing alternative kinase inhibitors with different core structures.
- Analyzing patent claims' breadth indicates limited overlap with existing inhibitors outside the core structure, providing some freedom for generic designs.
Summary of Patent Claims
| Category |
Description |
| Chemical Structure |
Heteroaryl core with substitutions at defined positions |
| Methods of Use |
Treatment of cancers with EGFR/HER2 expression, including combination therapies |
| Synthesis |
Specific synthetic routes to compounds claimed as novel |
| Formulations |
Pharmaceutical compositions including the compounds |
Conclusion
United States Patent 7,550,434 covers a targeted class of heteroaryl kinase inhibitors with specific structural and functional claims directed at cancer treatment. The patent's scope is sufficiently broad to include various compounds within the disclosed chemical space but limited by prior art barriers. The patent landscape indicates overlapping claims in kinase inhibitor space but no immediate challenges. The patent remains enforceable until 2028, with some freedom for development of alternative compounds outside the patent claims.
Key Takeaways
- The patent claims focus on heteroaryl compounds inhibiting EGFR/HER2 kinase activity.
- The chemical scope includes a defined genus of compounds with specific substitutions.
- The patent faces competing claims from prior art but maintains enforceability until approximately 2028.
- The landscape includes active patent filings globally, with overlapping technological fields.
- The patent could influence generic development, depending on the evolution of relevant claims.
FAQs
Q1: Does the patent cover any other kinase targets?
A: The claims are limited to inhibitors of EGFR and HER2 kinases. Other kinase targets are not explicitly included.
Q2: Are the chemical claims broad enough to cover all heteroaryl kinase inhibitors?
A: No, the claims are specific to the structural motifs disclosed and do not encompass all heteroaryl kinase inhibitors broadly.
Q3: How does prior art impact the patent’s strength?
A: Prior art with similar heteroaryl structures may challenge validity, but the patent’s specific substitutions and claimed utilities provide some differentiation.
Q4: When does the patent expire?
A: The patent is expected to expire around 2028, based on the 2008 filing date and a 20-year patent term.
Q5: Can generic companies develop similar kinase inhibitors?
A: Yes, if they design compounds outside the scope of the claims, especially with different core structures, they can avoid infringement.
References
[1] U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,550,434.
[2] European Patent Office. (2012). EP 2,500,902.
[3] Wang, Y., et al. (2014). Kinase inhibitor development and patent strategies. Journal of Medicinal Chemistry, 57(9), 3814-3820.
More… ↓
⤷ Start Trial
|
